Mitoxantrone and cisplatin in recurrent and/or metastatic salivary gland malignancies.

Abstract

A phase II study was performed to assess the safety and efficacy of mitoxantrone and cisplatin in locally recurrent and/or metastatic carcinomas of the salivary glands. Between May 1997 and March 2001, a total of 14 patients were entered on this trial. All of them had previously undergone radical resection and 10 were subsequently treated with adjuvant radiation therapy with (n=3) or without (n=7) concomitant chemotherapy. Therapy according to the study protocol consisted of mitoxantrone given as i.v. bolus on day 1 at a dose of 12 mg/m2 and cisplatin given as 90-min infusion at a dose of 30 mg/m2 on days 1-3. We observed two partial responses (14.3%) and stabilization of disease in nine patients (64.3%); progression during therapy was noted in only three cases (21.4%). The median time to progression was 15 months (range 2-36) and the median survival time was 27 months (range 4-54). Myelosuppression was commonly observed. Leukocytopenia occurred in all patients, and was grade 3 or 4 in three (21%) and four (29%) patients. WHO grade 3 thrombocytopenia and anemia was seen in three (21%) and four (29%) patients, respectively. Non-hematologic toxicity was in general mild to moderate except for two cases (14%) of grade 3 nausea and vomiting; overall incidence rates were nausea and vomiting (n=14), stomatitis (n=6), diarrhea (n=3), alopecia (n=11), infection (n=7), increase of serum creatinine (n=3), and peripheral neuropathy (n=3). The combination of mitoxantrone and cisplatin seems to be an active and fairly well-tolerated regimen for the treatment of advanced salivary gland cancers. According to the observed high rate of abrogating progressive disease for a long duration, and the resulting promising progression-free and overall survival time, further investigation seems warranted.

• Authors: Claudia Gedlicka, Birgit Schüll, Michael Formanek, Johannes Kornfehl, Martin Burian, Birgit Knerer, Edgar Selzer, Werner Scheithauer, Gabriela V Kornek
• Journal: Anti-cancer drugs (Anticancer Drugs) Vol. 13 Issue 5 Pg. 491-5 (Jun 2002) ISSN: 0959-4973 [Print] England
• PMID: 12045460 (Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article)

Chemical References

• Mitoxantrone
• Cisplatin

Topics

• Adult
• Aged
• Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
• Chemotherapy, Adjuvant
• Cisplatin (administration & dosage)
• Disease-Free Survival
• Drug Administration Schedule
• Humans
• Lung Neoplasms (drug therapy, secondary)
• Middle Aged
• Mitoxantrone (administration & dosage)
• Nausea (chemically induced)
• Neoplasm Recurrence, Local (drug therapy, pathology)
• Neutropenia (chemically induced)
• Palliative Care
• Salivary Gland Neoplasms (drug therapy, pathology)
• Survival Rate
• Treatment Outcome